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Abstract
Background: Disruption of the hypothalamic–pituitary–adrenal (HPA) axis, a neuroendocrine system associated
with the stress response, has been hypothesized to contribute to obesity development. This may be mediated
through epigenetic modulation of HPA axis-regulatory genes in response to metabolic stressors. The aim of this
study was to investigate adipose tissue depot-specific DNA methylation differences in the glucocorticoid receptor
(GR) and its co-chaperone, FK506-binding protein 51 kDa (FKBP5), both key modulators of the HPA axis.
Methods: Abdominal subcutaneous adipose tissue (ASAT) and gluteal subcutaneous adipose tissue (GSAT) biopsies
were obtained from a sample of 27 obese and 27 normal weight urban-dwelling South African women. DNA
methylation and gene expression were measured by pyrosequencing and quantitative real-time PCR, respectively.
Spearman’s correlation coefficients, orthogonal partial least-squares discriminant analysis and multivariable linear
regression were performed to evaluate the associations between DNA methylation, messenger RNA (mRNA)
expression and key indices of obesity and metabolic dysfunction.
Results: Two CpG dinucleotides within intron 7 of FKBP5 were hypermethylated in both ASAT and GSAT in obese
compared to normal weight women, while no differences in GR methylation were observed. Higher percentage
methylation of the two FKBP5 CpG sites correlated with adiposity (body mass index and waist circumference),
insulin resistance (homeostasis model for insulin resistance, fasting insulin and plasma adipokines) and systemic
inflammation (c-reactive protein) in both adipose depots. GR and FKBP5 mRNA levels were lower in GSAT, but not
ASAT, of obese compared to normal weight women. Moreover, FKBP5 mRNA levels were inversely correlated with
DNA methylation and positively associated with adiposity, metabolic and inflammatory parameters.
Conclusions: These findings associate dysregulated FKBP5 methylation and mRNA expression with obesity and
insulin resistance in South African women. Additional studies are required to assess the longitudinal association of
FKBP5 with obesity and associated co-morbidities in large population-based samples.
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Background
The pathophysiology of obesity involves a complex inter-
play between genetic and environmental influences [1].
The interaction between these factors in disease devel-
opment may be mediated through dysregulation of the
hypothalamic–pituitary–adrenal (HPA) axis, a neuroen-
docrine system that plays a critical role in maintaining
metabolic homeostasis in response to metabolic
stressors, such as chronically high ambient levels of
stress, reduced physical activity and consumption of high
caloric foods that are readily available in a Western soci-
ety [2]. The activity of the HPA axis is regulated by glu-
cocorticoids, which convey their signals through the
glucocorticoid receptor (GR), a transcriptional regulator
[3]. The sensitivity of cells to glucocorticoid action is
tightly regulated in part, through the interaction of GR
with the co-chaperone, FK506-binding protein 51 kDa
(FKBP5), which negatively regulates GR signaling by
inhibiting its binding to glucocorticoids and impeding
translocation to the nucleus [4]. In turn, FKBP5 expres-
sion is transcriptionally activated by GR, which binds
glucocorticoid response elements (GREs) present in the
FKBP5 promoter and distal intronic regions, thus form-
ing an ultra-short feedback loop [4]. Interestingly, a sin-
gle nucleotide polymorphism (SNP) in FKBP5,
specifically the T “risk allele” of the C/T SNP rs1360780
located in intron 2, has previously been demonstrated to
enhance FKBP5 transcription by moderating GR-
induced epigenetic changes at multiple intronic GREs,
including those within intron 7 [5].
Recently, increased DNA methylation of loci within GR
and FKBP5 has been identified as potential markers of
HPA axis dysfunction [6, 7]. DNA methylation involves the
covalent addition of a methyl group to carbon C5 of cyto-
sine dinucleotides to create 5-methylcytosine (5mC) [8].
This can result in an altered chromatin state and elicit
long-term changes in gene expression and pathological dys-
functions [8]. Importantly, unlike genetic mutations, DNA
methylation is reversible and therapies targeting DNA
methyltransferases have been successfully applied to the
management of certain neoplastic diseases [9]. Understand-
ing the role of DNA methylation modifications in HPA axis
regulation may lead to unique opportunities for preventive
and therapeutic interventions aimed at restoring HPA axis
function in metabolic diseases.
White adipose tissue (WAT), the primary site for energy
storage in mammals, is distributed throughout the body in
several depots which differ in structural organization, cellular
function and associated risk for developing metabolic disease
[10–12]. While abdominal obesity is more closely associated
with metabolic disease due to its greater contribution to the
systemic free fatty acid pool and chronic low-grade inflam-
mation, accumulation of lower body (i.e. gluteal) fat is associ-
ated with a reduced incidence of type 2 diabetes (T2D) and
cardiovascular disease (CVD), possibly owing to reduced
lipolytic potential and greater differentiation capacity of adi-
pocytes within this depot [13]. While the mechanisms under-
lying these depot differences in metabolic risk remain
elusive, it has been speculated that intrinsic variations in gene
expression and epigenetic signatures between adipose depots
may be responsible [11, 13, 14].
There is accumulating evidence to suggest that disrup-
tion of genes within the HPA axis may play a causal role
in obesity and associated metabolic diseases [15–27].
However, to the best of our knowledge, no studies have
examined the potential pathologic epigenetic modulation
of HPA axis-regulatory genes in adipose tissue, a highly
active endocrine organ and primary energy reservoir in
humans. The aim of the current study was therefore to
determine [1] the DNA methylation profiles of GR and
FKBP5 in gluteal (GSAT) and abdominal (ASAT) WAT
from obese and normal weight South African women,
and [2] the association of these methylation profiles with
markers of adiposity, insulin resistance and inflamma-
tory status. We propose that hypermethylation of GR
and FKBP5, key HPA axis-regulatory genes, is associated
with metabolic dysfunction and that assessing methyla-
tion patterns of GR and FKBP5 in GSAT and ASAT de-
pots may provide a better understanding of the intrinsic
differences between abdominal and lower body obesity.
Results
Participant characteristics
The characteristics of participants in this study have
been described in detail previously [28] and are summa-
rized in Table 1. The participants were all female,
51.85% black and 48.15% white South African. The
obese women were significantly older than normal
weight women (p = 0.004). There were no significant
differences in socioeconomic score (SES), current smok-
ing status or weekly alcohol consumption between obese
and normal weight women.
By design, all measures of body composition and fat
distribution were greater in obese compared to normal
weight women. While no differences in fasting glucose
levels were observed between the groups, the obese
women displayed higher systemic inflammation (as mea-
sured by c-reactive protein), hyperinsulinemia and insu-
lin resistance (as measured by homeostasis model for
insulin resistance (HOMA-IR), increased leptin and re-
duced adiponectin concentrations) and reduced insulin
sensitivity (SI) compared to normal weight women.
GR and FKBP5 methylation analyses
We used pyrosequencing to analyse 18 CpG sites situ-
ated within exon 1F of the proximal GR promoter (Fig.
1a), as well as 13 CpG sites within intron 2 and two
CpG sites within intron 7 of FKBP5 (Fig. 1b).
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Table 1 Participant characteristics
Normal weight (n=27) Obese (n=27) P value
DEMOGRAPHIC AND LIFESTYLE FACTORS
Age (years) 24 (22-26) 28 (24-36) 0.004
Ethnicity
Blacka 14 (51.9) 14 (51.9)
SES 16.8 (11.6-22.6) 20.1 (10.6-23.1) 0.843
Smoking (yes)a 7 (25.9) 7 (25.9) 0.936
Alcohol consumption (g) 4.7 (0-24.6) 3.8 (0-16.1) 0.854
BODY COMPOSITION
BMI (kg/m2) 22.9 (21.7-23.7) 38.3 (34.3-41.6) <0.001
Fat (%) 29.7 (25.9-35.1) 47.0 (43.5-49.6) <0.001
BODY FAT DISTRIBUTION
Waist circumference (cm) 78.3 (74.0-82.0) 112.5 (102.6-118.5) <0.001
GSAT (kg) 4.6 (4.0-5.2) 5.9 (5.4-6.5) 0.001
ASAT (cm2) 169.7 (134.7-225.6) 558.2 (480.2-620.3) <0.001
VAT (cm2) 54.3 (42.6-77.2) 107.7 (80.3-173.7) <0.001
METABOLIC PARAMETERS
Fasting Glucose (mmol/L) 4.4 (4.1-4.6) 4.5 (4.4-4. 7) 0.027
Fasting Insulin (mU/L) 5.1 (3.5-8.5) 12.5 (7.1-16.9) 0.001
HOMA-IR 0.9 (0.7-1.7) 2.5 (1.1-3.3) <0.001
SI (·10
-4 min-1/[μU/ml]) 4.1 (1.4-6.2) 1.8 (1.0-3.6) 0.011
C-reactive protein (mg/l) 1.2 (0.6-3.8) 7.9 (3.4-8.7) <0.001
Adiponectin (ng/ml) 6.5 (4.1-9.5) 3.5 (2.1-5.8) <0.001
Leptin (ng/ml) 15.2 (7.8-20.5) 59.0 (47.9-66.2) <0.001
Data expressed as the median (25th–75th percentile) or as acount (percentage)
Abbreviations: BMI body mass index, GSAT gluteal subcutaneous adipose tissue, HOMA-IR Homeostatic model of insulin resistance, SAT subcutaneous adipose
tissue, SES socioeconomic score, SI insulin sensitivity index, VAT visceral adipose tissue
Fig. 1 Schematic diagram of the a GR and b FKBP5 genes, illustrating the CpG sites analysed in the proximal 1F promoter and introns 2 and 7,
respectively. The transcription start sites and glucocorticoid response elements (GREs) within FKBP5 are indicated
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Methylation of GR and FKBP5 were analysed in GSAT
and ASAT biopsies as representatives of lower body and
central obesity, respectively.
Results revealed low GR methylation levels in both
GSAT (Fig. 2a) and ASAT (Fig. 2b) depots, as well as
a large degree of inter-individual variation at all CpG
sites, irrespective of obesity. In GSAT, GR methyla-
tion appeared to be lower in obese women compared
to normal weight women, although these differences
were not significant (Fig. 2a). No consistent differ-
ences in DNA methylation patterns in ASAT were
observed between obese compared to normal weight
women (Fig. 2b).
An analysis of FKBP5 intron 2 methylation levels in
GSAT and ASAT revealed no significant differences be-
tween obese compared to normal weight women (Fig. 3a,
b). For FKBP5 intron 7, methylation levels of CpG542
(137,847 bp from TSS) and CpG543 (137,872 bp from
TSS) were approximately 10% higher in obese com-
pared to normal weight women (GSAT, p < 0.001;
ASAT, p < 0.001), which was consistent for both de-
pots (Fig. 3a, b).
FKBP5 methylation associations with obesity and
parameters of metabolic function
The differential methylation patterns observed in obese
versus normal weight women prompted us to further ex-
plore the associations of these CpG sites with clinical
and biochemical features of obesity and metabolic dys-
function. We explored DNA methylation associations
using orthogonal partial least-squares discriminate ana-
lysis (OPLS-DA) (Fig. 4). The OPLS score plot for each
model revealed a separation between the obese and nor-
mal weight women (Fig. 4, top panels). The loading plots
(Fig. 4, lower panels), which signify the basis of the score
plot clustering, revealed that CpG542 and CpG543 were
Fig. 2 Pyrosequencing analysis of GR methylation in gluteal (GSAT) and abdominal (ASAT) adipose tissue. Percentage methylation of individual
CpG sites in GSAT (a) and ASAT (b) of normal weight and obese South African women. Data represented as mean ± SD. (GSAT, n = 27 per group;
ASAT, n = 13-22 per group)
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highly correlated between ASAT and GSAT (CpG542: rs
= 0.698, p < 0.001; CpG543: rs = 0.765, p < 0.001), and
positively associated with measures of adiposity, including
BMI and waist circumference (WC) in both adipose de-
pots. Similarly, positive associations were observed for
markers of insulin resistance (HOMA-IR, fasting insulin,
reduced insulin sensitivity, increased leptin and reduced
adiponectin) and systemic inflammation (c-reactive pro-
tein). CpG542 and CpG543 methylation also significantly
associated with ethnicity and SES in both depots. Add-
itionally, CpG543 methylation associated with alcohol
consumption in ASAT. Consequently, all associations
were adjusted accordingly for significant covariates. When
the adjustments were made, all associations were main-
tained; however, the associations with insulin sensitivity
lost statistical significance (Table S1).
GR and FKBP5 mRNA expression levels in SAT
To examine whether altered CpG methylation corre-
sponded with changes in GR and FKBP5 expression, we
measured their messenger ribonucleic acid (mRNA) sta-
tus in GSAT and ASAT using quantitative real-time
PCR (qRT-PCR). GSAT from obese women had ~ 30%
lower GR mRNA expression levels (p < 0.010) compared
to normal weight women (Fig. 5a), while no differences
were observed in ASAT (Fig. 5b). Similarly, FKBP5
mRNA expression levels in GSAT were reduced by ~
40% in obese compared to normal weight women (Fig.
5c) but was unchanged in ASAT (Fig. 5d). Correlation
analyses revealed a significant inverse relationship be-
tween FKBP5 mRNA levels and CpG542/3 methylation
in GSAT, but not in ASAT (Fig. 5e, f). Furthermore,
FKBP5 mRNA negatively associated with markers of
Fig. 3 Pyrosequencing analysis of FKBP5 methylation in gluteal (GSAT) and abdominal (ASAT) adipose tissue. Percentage methylation of individual
CpG sites in GSAT (a) and ASAT (b) of normal weight and obese South African women. Data represented as mean ± SD. (GSAT, n = 27 per group;
ASAT, n = 13–22 per group). Statistical significance analysed using OPLS-DA. ****p < 0.0001
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adiposity, insulin resistance and systemic inflammation
in GSAT, but not in ASAT (Table S2).
Effect of rs1360780 SNP on FKBP5 methylation and gene
expression
In order to assess the potential moderating role of the
rs1360780 SNP on FKBP5 methylation and gene expres-
sion data in our study, we genotyped all participants’
SAT samples for this SNP. Using the combined sample of
obese and normal weight participants, we determined the
genotype frequencies to be 0.44 (n = 21), 0.38 (n = 19) and
0.16 (n = 6) for the CC, CT and TT (rare homozygous “risk
allele”) genotypes, respectively, and we observed no signifi-
cant deviations from the Hardy-Weinberg equilibrium in this
sample population (p = 0.12) (data not shown).
We next stratified the samples based on genotype and
observed no significant differences in FKBP5 methylation
at CpG543 (Fig. 6a) or CpG543 (Fig. 6b) between the CC,
CT and TT genotypes in both GSAT and ASAT depots.
Similarly, no differences were observed in FKBP5 mRNA
expression between any of the genotypes in GSAT (Fig.
6c) or ASAT (Fig. 6d). Taken together, these data demon-
strate that FKBP5 methylation and gene expression levels
in obese and normal weight women in our study were not
influenced by the rs1360780 SNP.
Discussion
Obese individuals have a higher risk of developing T2D and
CVD; however, these diseases are often diagnosed years after
the onset of insulin and glucose dysregulation, during which
micro- and macrovascular complications can occur. It is thus
crucial to understand the early pathogenic mechanisms of
obesity and insulin resistance sequelae in order to develop
early preventative interventions. Our present data provide
Fig. 4 Multivariate analysis of adiposity (BMI and waist circumference (WC)), markers of insulin sensitivity (HOMA-IR, fasting insulin), plasma
adipokines (increased leptin and reduced adiponectin), systemic inflammation (c-reactive protein), sociodemographic factors [age, ethnicity,
socioeconomic status (SES), alcohol consumption and smoking status] and DNA methylation of FKBP5 CpG542 and CpG543 in GSAT and ASAT
from obese and normal weight women (OPLS-DA, CV-ANOVA: p < 0.0001). Top panels: OPLS-DA cross-validated scores that describe participant
variability. Lower panels: the body composition, sociodemographic, insulin sensitivity, inflammation, adipokines and FKBP5 methylation (OPLS
weights, w [1] with 95% CI) that discriminate between obese [2] and normal weight [1] women
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novel evidence that DNA methylation of two intronic CpG
sites in FKBP5, a key player of the HPA axis and stress re-
sponse, is altered in SAT from obese compared to normal
weight women. Moreover, multivariable regression analysis of
these CpG sites revealed a positive relationship with measures
of adiposity (BMI and waist circumference), insulin resistance
(HOMA-IR, fasting insulin, increased leptin and reduced adi-
ponectin levels) and systemic inflammation (CRP), all of which
are established risk factors for T2D and CVD.
Our analysis of GR methylation within exon 1F re-
vealed considerable inter-individual variability in our
sample population. This is consistent with a previous
study assessing methylation of the same GR promoter
region in patients with subclinical atherosclerosis [27]
and also agrees with other epigenetic studies in complex
diseases [29]. While the magnitude of GR methylation
alterations between obese and normal weight women are
less pronounced compared to those identified in, for ex-
ample, various types of malignant disorders [30, 31], they
are consistent with genome-wide association studies
showing subtle changes in GR methylation, including
sites within exon 1F, in numerous disorders [32–34].
Furthermore, GR mRNA expression was downregulated
in GSAT from our obese study population [19], and al-
though its expression did not correlate with methylation
levels (data not shown), it is now widely accepted that
DNA methylation marks are functionally complex and
may orchestrate other important regulatory events, in-
cluding alternative splicing and even the promotion of
gene transcription [8]. However, we cannot rule out the
Fig. 5 GR and FKBP5 mRNA expression in gluteal (GSAT) and abdominal (ASAT) adipose tissue. Relative mRNA expression of GR in GSAT (a) and
ASAT (b) and FKBP5 in GSAT (c) or ASAT (d) from normal weight (NW) and obese South African women. Data represent mean ± SD (GSAT, n = 27
per group; ASAT, n = 13–22 per group). Spearman’s correlation analysis of FKBP5 CpG542 and CPG543 methylation and FKBP5 mRNA levels in
GSAT (e) and ASAT (f) from normal weight and obese black and white South African women (n = 27 per group). Linear regression lines used for
descriptive purposes only
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possibility of other genetic/epigenetic mechanisms
underlying GR regulation in this study, such as the pres-
ence of SNPs or inhibition by non-coding RNAs and/or
histone modifications [22, 35].
While FKBP5 has been extensively studied in the con-
text of neuropsychiatric diseases [5, 36–39], several re-
cent studies have uncovered a metabolic role for this
gene [40]. Indeed, preclinical studies using animal
models have demonstrated that deletion of the FKBP5
gene protects mice from diet-induced obesity and hep-
atic steatosis, and pharmacological inhibition of FKBP5
improves their metabolic health [41, 42]. In humans, gen-
etic variants and hypomethylation within intron 2 of FKBP5
have been associated with Cushing’s syndrome [24]. FKBP5
SNPs have also been linked to insulin resistance and T2D
traits [23, 25] and reduced weight loss following bariatric sur-
gery [43]. More recently, hypermethylation of two CpG sites
in FKBP5 intron 2 in peripheral blood were associated with
metabolic risk and cardiovascular disease traits, including
BMI and WC, in individuals with T2D [44]. While this study
was limited by a small sample size, it agrees with our findings
on the association between higher intronic FKBP5 methyla-
tion and an increased risk for obesity and insulin resistance.
In agreement with the longstanding association of
DNA methylation with gene silencing, we observed that
CpG542 and CpG543 hypermethylation in obese women
inversely correlated with FKBP5 transcript levels in
GSAT. Although these CpGs do not reside within the
proximal FKBP5 promoter, it is now appreciated that
many steroid-regulated genes lack response elements in
their promoters and are rather regulated through distal
binding sites [45]. Furthermore, while it was beyond the
scope of this study to elucidate the transcription factors
that occupy and regulate this region, we note that
CpG542 and CpG543 are located either directly within,
or flank, biologically validated consensus glucocorticoid
response elements (GREs), which have been shown to
come into direct contact with the FKBP5 transcriptional
start site and RNA polymerase II, via three-dimensional
chromatin loops, and influence FKBP5 transcription
[39]. In agreement with this are several reports demon-
strating that exposure of human peripheral blood cells
Fig. 6 Genotype effect of rs1360780 on FKBP5 CpG542 (a) and CpG543 (b) methylation and relative mRNA expression levels in gluteal (GSAT) (c)
and abdominal (ASAT) (d) adipose tissue from normal weight and obese South African women. Data represent mean ± SD
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to dexamethasone, a GR agonist, can induce rapid de-
methylation and transcription of FKBP5 via these GREs
[5, 46]. Furthermore, while previous studies have shown
that FKBP5 demethylation and mRNA induction by GR
is influenced by the rs1360780 SNP in human peripheral
blood from both African American and Caucasian popu-
lations [5, 46–48], this was not observed in our study, al-
beit in a limited sample size. These findings may suggest
that FKBP5 regulation is tissue-specific; however, con-
firmation of this in larger, more representative studies is
required.
Obesity is characterized by a state of chronic, low-
grade inflammation, which may be a key mechanism
underlying the development of several obesity-associated
diseases including T2D and CVD. Higher levels of in-
flammatory cytokines have been shown to cause a
downregulation of GR expression and/or functionality of
the receptor, resulting in glucocorticoid resistance, a
condition characterized by insensitivity of tissues to the
actions of glucocorticoids [49]. In adipose tissue, the de-
velopment of glucocorticoid resistance by tumour necro-
sis factor α (TNFα) treatment was also shown to inhibit
GR function by promoting the expression of GRβ, a nu-
clear localized GR isoform which acts as a dominant
negative of GRα transcriptional activity [50]. Interest-
ingly, the obese women in our study had a more proin-
flammatory adipose tissue profile [51], including
elevated expression levels of TNFα and migration inhibi-
tory factor cytokines, as well as the CCL2 chemokine
and macrophage markers, CD68 and CD163, which was
accompanied by reduced GRα mRNA compared to nor-
mal weight women [51]. This observation corroborates
Fig. 7 Schematic proposed model of study findings showing how metabolic stressors lead to obesity and inflammation-induced downregulation
of GR, possibly through glucocorticoid resistance and induction of the non-ligand binding GRβ isoform, and consequently, hypermethylation of
FKBP5 at selected CpGs (CpG542 and CpG543) located within intron 7 in subcutaneous adipose tissue. Reduced FKBP5 mRNA expression would
result in a loss of the ultra-short negative feedback loop between FKBP5 and GR (grey arrows), thus altering the biologic response to
glucocorticoids. DNA methylation alterations in FKBP5 CpG542/3 are associated with increased clinical risk factors for disease, including adiposity
(high BMI, WC and leptin), inflammation (high CRP) and insulin resistance (elevated fasting insulin and HOMA-IR, low adiponectin) and reduced
insulin sensitivity. This figure was created using BioRender (https://biorender.com/)
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with other studies demonstrating a negative association
between GRα mRNA levels and measures of inflamma-
tion, obesity and insulin resistance [17, 49, 52].
Based on this, we propose a model whereby obesity-
and inflammation-induced downregulation of GR, and
possible induction of GRβ, may augment FKBP5 methy-
lation and, consequently, reduce FKBP5 transcription in
GSAT (Fig. 7). These events, in turn, result in a loss of
the ultra-short negative feedback loop between FKBP5
and GR, thus altering the biologic response to glucocor-
ticoids. The change in glucocorticoid sensitivity in
GSAT, triggered by low GR, may represent a beneficial
feedback mechanism protecting adipocytes from dysreg-
ulated HPA axis activity during the progression of obes-
ity and insulin resistance. It is unclear why GR and
FKBP5 mRNA levels were not similarly reduced in
ASAT. It is possible that statistical significance was not
obtained due to the use of a smaller sample size available
for this tissue type. Alternatively, the effects on GR sig-
naling may be dampened in this depot due to ethnic dif-
ferences in inflammatory profiles of SAT between black
and white women in our study population. Indeed, a
previous study using the same sample population
showed that GSAT from black women had higher ex-
pression of inflammatory cytokines, macrophage
markers and leptin compared to ASAT [52].
Our study has several strengths. To our knowledge,
this is the first study to assess both GR and FKBP5 DNA
methylation in the same population of obese and normal
weight individuals, providing a more comprehensive un-
derstanding of the interplay between these genes. More-
over, in contrast to most DNA methylation studies in
obesity, we assessed GR and FKBP5 methylation levels in
adipose tissue rather than peripheral blood. Adipose tis-
sue is the primary affected organ during the development
of obesity, and to date, few DNA methylation studies have
been performed using this tissue type. The comparisons
that were made between gluteal and abdominal SAT fur-
ther strengthen this study, as they enabled the exploration
of unique features that may contribute to the variability in
associated metabolic risk between these depots. Indeed,
notable differences in the magnitude of metabolic risk as-
sociations (as determined by multivariable regression β-
coefficients) were observed for CpG542 in ASAT and
GSAT, whereas the β-coefficients for CpG543 associations
were relatively similar between depots. This observation
raises the possibility that the role of CpG543 methylation
is more highly conserved between the different adipose
depots compared to CpG542, although additional experi-
ments are required to confirm this.
Several limitations should also be noted when inter-
preting the results of this study. Firstly, adipose tissue
contains a vascular-stromal fraction in which macro-
phages, fibroblasts, endothelial cells and preadipocytes
reside, and we therefore cannot exclude the possible
contribution of these cell types to the DNA methylation
profiles obtained for GR and FKBP5 in our study. While
we acknowledge that many studies using whole blood,
for example, control for cellular heterogeneity by meas-
uring DNA methylation in individual cell types following
cell sorting or adjusting for direct measured cell counts,
we were unable to do this in our study due to limited
availability of tissue. Furthermore, whereas the use of
post hoc regression models to adjust for blood cell mix-
ture is facilitated by the availability of reference datasets
on cell types in blood, to the best of our knowledge,
such reference datasets are not available for adipose tis-
sue and also may not be representative of our study
population [53]. Another study limitation is the use of
only female participants from South Africa, and there-
fore, the generalizability to other race/ethnic groups, or
males, is unknown. Furthermore, as a result of our
cross-sectional study design, the causal relationship be-
tween methylation changes and obesity or metabolic
traits cannot be determined, and these warrant further
investigation in larger, longitudinal study cohorts. While
pyrosequencing is a highly sensitive and reliable method
for DNA methylation analysis, it only allows for the inves-
tigation of small genomic regions [54]. It is therefore pos-
sible that our analysis does not reflect the methylation
effect of other genomic regions of GR and FKBP5. In par-
ticular, FKBP5 contains numerous transcriptional regula-
tory regions which are distributed throughout the gene,
including the promoter and other intronic enhancer re-
gions which harbour functional GREs [5, 46] as well as
CCCTC-binding factor (CTCF) sites [46]. Our analysis of
the effect of the rs1360780 SNP on FKBP5 methylation
and gene expression levels should also be interpreted in
the context of a small sample size, and larger, more repre-
sentative studies will be required to confirm this finding.
Lastly, the molecular function of FKBP5 in adipose tissue
during the progression of obesity remains to be elucidated.
FKBP5 knockout adipocyte cell culture models may shed
light on this and forms part of future studies.
Conclusions
Our study findings provide the first demonstration of an
association between FKBP5 methylation in intron 7 in
SAT and established markers of obesity and metabolic
risk [55, 56]. While these findings are purely correlative
and cannot be used to determine causality, they add to a
growing list of studies marking aberrant DNA methyla-
tion of HPA axis genes as clinically meaningful risk fac-
tors for metabolic diseases [57]. Future studies using
longitudinal cohorts should shed light on whether
FKBP5 hypermethylation is a cause or consequence of
metabolic dysregulation. Moreover, it remains to be de-
termined whether altered FKBP5 methylation patterns in
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SAT are reflected in blood, which could be used to as-
sess potential risk of developing metabolic disease. Given
the long time-course of T2D development and the re-
versible nature of epigenetic changes, our results demon-
strate the significance of the HPA axis in metabolic
dysfunction and mark constituents of this pathway as
potential targets for preventative and therapeutic inter-
ventions for obesity and its complications.
Methods
Study population
The study was approved by the Human Research Ethics
Committee of the Faculty of Health Sciences of the Uni-
versity of Cape Town. The study sample consisted of 27
obese (body mass index (BMI) ≥ 30 kg/m2) and 27 nor-
mal weight (BMI < 25 kg/m2) premenopausal, urban-
dwelling South African women who were recruited as
previously described [28]. All participants were of self-
reported European or Black African (Xhosa) ancestry (both
parents), aged 18–45 years without any known diseases, were
not pregnant or lactating and were not taking medication for
diabetes, hypertension, human immunodeficiency virus/ac-
quired immunodeficiency syndrome (HIV/AIDS) or other
metabolic-related disorders. Informed, written consent was
obtained from each participant prior to testing.
Participants characteristics
Assessment of demographic and lifestyle factors
Baseline information was obtained from participants
using standardized questionnaires as previously de-
scribed [28]. Briefly, questionnaire information included
participant demographics, age, race, current smoking
status, level of alcohol consumption (estimated using a
food frequency questionnaire) and information on asset
index, education level, household crowding and employ-
ment status which were used to calculate a socioeco-
nomic score (SES) as previously described [51].
Body composition
Assessment of body composition was described in detail
previously [28]. Basic anthropometric measurements in-
cluding height, weight and waist circumference were re-
corded and BMI was calculated as weight (kg)/height2
(m2). Total fat mass and gluteal subcutaneous adipose
was measured by dual-energy X-ray absorptiometry
(DXA; Discovery-W, Software version 12.6; Hologic Inc.,
Bedford, MA, USA) while visceral and abdominal tissue
mass was measured by computerized tomography (CT;
Toshiba X-press Helical Scanner, Tokyo, Japan) [28].
Biochemical and metabolic analysis
After an overnight fast, blood samples were drawn for
the measurement of plasma glucose and serum insulin
concentrations, which were used to estimate insulin
resistance, based on the homeostasis model of insulin re-
sistance (HOMA-IR) [58]. Participants underwent an
insulin-modified frequently sampled intravenous glucose
tolerance test (FSIGT) as previously described [59], from
which the insulin sensitivity index (SI) was measured
using Bergman’s minimal model of glucose kinetics [60].
Fat biopsies
Adipose tissue biopsies were obtained from superficial
abdominal subcutaneous adipose tissue (ASAT) and glu-
teal subcutaneous adipose tissue (GSAT) depots using a
mini liposuction method as previously described [51].
The tissues were placed in vials, snap frozen in liquid ni-
trogen and stored at − 80oC for subsequent gene expres-
sion and DNA methylation analysis.
DNA extraction
Genomic DNA was extracted from GSAT and ASAT
using the QIAamp DNA kit (Qiagen. Valencia, CA,
USA) according to the manufacturer’s instructions.
DNA quality and concentrations were assessed using the
NanoDrop ND-1000 Spectrophotometer (NanoDrop
Products, Wilmington, USA) and Qubit fluorometer
(Life Technologies, CA, USA), respectively.
Bisulfite conversion
Treatment of DNA with sodium bisulfite converts all
unmethylated cytosine bases into uracil, allowing for the
identification of methylated, unconverted cytosines by
pyrosequencing [61]. Bisulfite conversion of genomic
DNA from adipose tissue biopsies were performed using
the EpiTect DNA kit (Qiagen, Hilden, Germany), ac-
cording to the manufacturer’s instructions. The follow-
ing PCR conditions were used for the conversion: 95 °C
for 5 min, 60 °C for 10 min, 95 °C for 5 min, 60 °C for 10
min and 4 °C for less than 20 h. Bisulphite-treated DNA
were desulphonated, washed and eluted prior to use in
PCR and pyrosequencing experiments.
Pyrosequencing
Percent DNA methylation of GR and FKBP5 was deter-
mined by pyrosequencing. The GR gene has nine alter-
native first exons that are controlled independently by
separate promoters [15]. Exon 1F, situated within a 3-kb
CpG island, is the most widely studied, and differential
methylation of CpGs within this region has been previ-
ously associated with subclinical atherosclerosis [27].
Thus, for the current study, pyrosequencing assays were
designed to this region. For FKBP5, we assessed CpG
sites within introns 2 and 7 which span experimentally
validated GREs and have previously been implicated in
metabolic disorders [15, 24, 44]. All pyrosequencing as-
says were designed by EpigenDX (Worcester, MA, USA).
PCR of 25 ng bisulfite converted DNA was carried out
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using the PyroMark PCR Kit (Qiagen, Valencia, CA,
USA) under the following PCR conditions: GR (Epi-
genDX assay ADS1342): 95 °C for 15 min; 45 × (95 °C
for 30 s; 56 °C for 30 s; 72 °C for 30 s); 72 °C for 5 min;
GR (EpigenDX assay ADS2386): 95 °C for 15 min; 45 ×
(95 °C for 30 s; 54 °C for 30 s; 72 °C for 30 s); 72 °C for
5 min; FKBP5 (EpigenDX assay ADS3269): 95 °C for 15
min; 45 × (95 °C for 30 s; 60 °C for 30 s; 68 °C for 30 s);
68 °C for 5 min; FKBP5 (EpigenDX assay ADS3828): 95
°C for 15 min; 45 × (95 °C for 30 s; 56 °C for 30 s; 68 °C
for 30 s); 68 °C for 5 min. PCR reactions were carried
out in a Veriti 96-well Thermal Cycler (Thermo Fisher,
Waltham, MA, USA). The quality of PCR amplicons was
assessed by agarose gel electrophoresis and amplicons
were stored at 4 °C until pyrosequencing. Single-
stranded amplicons were annealed to pyrosequencing
primers (EpigenDX, Worcester, MA, USA) and sub-
jected to primer extension and nucleotide incorporation
using the PyroMark Q96 MD pyrosequencer and Pyro-
Mark Gold Q95 reagents (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Sequencing
analysis was performed using the PyroMark Q96 soft-
ware (Version 1.0.10; Qiagen) program, which deter-
mined percent DNA methylation at all CpG
dinucleotides downstream of the annealed primer at >
90% precision. All pyrosequencing assays were validated
using different ratios of methylated:unmethylated bisul-
fite converted DNA (0, 10, 25, 50, 75, 90 and 100%)
(Qiagen, Valencia, CA, USA), from which standard
curves were constructed to determine primer sensitivity
(Fig. S1). Pyrosequencing assay validation also included
quality controls containing either of the following: se-
quencing primer and annealing buffer only; biotinylated
PCR primer and annealing buffer only; sequencing pri-
mer, biotinylated PCR primer and annealing buffer only;
PCR product and annealing buffer only; PCR no tem-
plate control, sequencing primer and annealing buffer
only. Each pyrosequencing run contained no template
negative controls, and bisulfite conversion controls were
incorporated within each assay sequence to assess con-
version efficiency. Assays were repeated if any of the in-
built quality control measures were flagged. The
nomenclature of GR and FKBP5 CpGs are based on
their sequencing identities from EpigenDX (Worcester,
MA, USA).
RNA extraction, reverse transcription and real-time PCR
Total RNA was extracted from GSAT and ASAT biop-
sies using the RNeasy/miRNeasy mini Kit (Qiagen, CA,
USA) according to the manufacturer’s instructions. RNA
quantity and purity were determined using the Nano-
Drop ND-1000 Spectrophotometer (NanoDrop Prod-
ucts, DE, USA). Complementary DNA (cDNA) was
synthesized using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, CA, USA), and
mRNA levels of FKBP5, GR and reference genes 18S,
PPIA and RPLP0 quantified using TaqMan Universal
PCR Master Mix and TaqMan gene expression assays
(Applied Biosystems, CA, USA), according to the manu-
facturer’s instructions. Relative expression levels were
calculated using the standard curve method. Normfin-
der, a mathematical model of gene expression [62], was
used to confirm the stable expression of the reference
genes and identified RPLP0 as the best normalization
gene. Thus, expression levels were normalized to the
RPLP0 endogenous control.
FKBP5 SNP genotyping
The FKBP5 rs1360780 (C/T) polymorphisms were geno-
typed using qRT-PCR with Taqman genotyping assays
(Applied Biosystems, Massachusetts, USA) on the Quant-
Studio™ 7 Flex Real-Time PCR System (Applied Biosys-
tems, Massachusetts, USA). Briefly, qRT-PCR was
performed using 9.4 ng of DNA, 5 μl of Taqman Master
Mix and 0.25 μl of 40× TaqMan SNP genotyping assay in
a total volume of 10 μl, according to the manufacturer’s
instructions. The following PCR conditions were used: 10
min at 95 C (initial denaturation/enzyme activation), 15 s
at 95 C (denaturation) and 60 s at 60 C (annealing/exten-
sion) for 40 cycles. For quality control, eight samples were
randomly selected and genotyped in duplicate. Positive
and negative controls were included on all plates.
Statistical analysis
Data are presented as the mean and standard deviation
(SD) if normally distributed or the median and inter-
quartile range (25th and 75th percentile) if not normally
distributed. The Shapiro-Wilk test was used to test for
normality. Student’s t tests (normal distribution) and
Mann-Whitney tests (non-normal distribution) were
used to compare anthropometric, metabolic and gene
expression differences between obese and normal weight
women. In order to explore site-specific DNA methylation
differences between obese and normal weight women, as
well as to examine associations with metabolic parame-
ters, multivariable analysis was used. This analysis helps to
avoid multiple comparisons and has the ability to deal
with correlated variables. Firstly, the complete dataset was
inspected using principal component analysis (PCA) to
detect groupings and outliers. We then performed orthog-
onal partial least-squares discriminate analysis (OPLS-DA)
to examine differences in site-specific DNA methylation
between obese and normal weight women. The CpG sites
that were differentially methylated between obese and
normal weight women were then used in OPLS analysis to
explore associations with measures of insulin sensitivity,
body composition, plasma adipokines, systemic inflamma-
tion, sociodemographic and lifestyle factors. The models
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were validated based on analysis of variance (ANOVA) of
the cross-validated OPLS scores (CV-ANOVA) for signifi-
cance testing [63]. Variables were considered significant
when fulfilling the statistical significance criteria using
post hoc linear regression on loadings calculated from the
validated OPLS models using a 95% confidence level [64].
Multivariable linear regression was then conducted to ex-
plore the associations between the DNA methylation sites
and the metabolic outcomes, adjusting for significant con-
founding factors, shown in the OPLS models. The correl-
ation between differentially methylated CpG sites and
mRNA levels, and association of mRNA levels with meta-
bolic parameters, were assessed using Spearman’s correl-
ation analysis. Since mRNA levels did not correlate with
lifestyle and sociodemographic variables, no post hoc ad-
justments were made for these data. Genotype-stratified
DNA methylation and gene expression data were com-
pared between obese and normal weight women using the
non-parametric Kruskal-Wallis test. Hardy-Weinberg
equilibrium of the genotyped FKBP5 SNP (rs1360780)
was tested using a chi-square goodness of fit test. Data
were analysed using STATA version 14.0 (StataCorp, Col-
lege station, TX, USA), GraphPad Prism (v8.2.1) and
SIMCA v. 15.02. Significance was accepted as p < 0.05.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-00932-3.
Additional file 1: Figure S1. Sensitivity of pyrosequencing assays used
to interrogate GR and FKBP5. Standard curves for GR CpG-226 to CpG-217
(A), GR CpG-209 to CpG-202 (B), FKBP5 CpG -585 to CpG-573 (C) and
FKBP5 CpG542 and CpG543 (D). Table S1. Correlation between DNA
methylation and cardiometabolic risk factors. Data expressed as the β-
coefficient (p-value) adjusted for ethnicity, socioeconomic status and *al-
cohol consumption. Abbreviations: ASAT, abdominal subcutaneous adi-
pose tissue; BMI, body mass index; CRP, c-reactive protein; GSAT, gluteal
subcutaneous adipose tissue; HOMA-IR, Homeostatic model assessment-
insulin resistance; SI, insulin sensitivity index; WC, waist circumference.
Table S2. Correlation between FKBP5 mRNA levels and cardiometabolic
risk factors. Data expressed as the Spearman’s r-coefficient (p-value). Ab-
breviations: ASAT, abdominal subcutaneous adipose tissue; BMI, body
mass index; CRP, c-reactive protein; GSAT, gluteal subcutaneous adipose
tissue; HOMA-IR, Homeostatic model assessment-insulin resistance; SES,
socioeconomic status, SI, insulin sensitivity index; WC, waist
circumference.
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